We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive top-line data from a phase II study evaluating its investigational pipeline candidate, cemdisiran, for the treatment of immunoglobulin A nephropathy ("IgAN").
Alnylam is developing cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
Data from the above-mentioned study showed that treatment with cemdisiran led to a 37% mean reduction from base line in the 24-hour urine protein to creatinine ratio relative to placebo — the primary endpoint of the study.
The study data of secondary endpoints were similar to a therapeutic benefit of cemdisiran in IgAN. There were no significant drug-related safety signals.
Alnylam and Regeneron are planning for the phase III development of cemdisiran in IgAN.
Per the company, the data on cemdisiran demonstrates what is believed to be clinically meaningful reductions in proteinuria — which is an important prognostic factor in IgA nephropathy.
Though the overall safety and tolerability profile supports the clinical development of cemdisiran monotherapy in patients with IgAN, one death was reported in the cemdisiran arm related to a post-surgical complication. However, it was not related to the study drug.
Shares of Alnylam were down 3.2% on Thursday following the announcement of the news. The stock has plunged 20.4% so far this year compared with the industry’s decrease of 22.8%.
Image Source: Zacks Investment Research
Alnylam, in collaboration with Regeneron, is advancing cemdisiran for the treatment of complement-mediated diseases.
Regeneron is advancing a phase III study of cemdisiran and pozelimab combination for treating myasthenia gravis.
Alnylam records collaboration revenues from its collaboration with REGN.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimates have narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive top-line data from a phase II study evaluating its investigational pipeline candidate, cemdisiran, for the treatment of immunoglobulin A nephropathy ("IgAN").
Alnylam is developing cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
Data from the above-mentioned study showed that treatment with cemdisiran led to a 37% mean reduction from base line in the 24-hour urine protein to creatinine ratio relative to placebo — the primary endpoint of the study.
The study data of secondary endpoints were similar to a therapeutic benefit of cemdisiran in IgAN. There were no significant drug-related safety signals.
Alnylam and Regeneron are planning for the phase III development of cemdisiran in IgAN.
Per the company, the data on cemdisiran demonstrates what is believed to be clinically meaningful reductions in proteinuria — which is an important prognostic factor in IgA nephropathy.
Though the overall safety and tolerability profile supports the clinical development of cemdisiran monotherapy in patients with IgAN, one death was reported in the cemdisiran arm related to a post-surgical complication. However, it was not related to the study drug.
Shares of Alnylam were down 3.2% on Thursday following the announcement of the news. The stock has plunged 20.4% so far this year compared with the industry’s decrease of 22.8%.
Image Source: Zacks Investment Research
Alnylam, in collaboration with Regeneron, is advancing cemdisiran for the treatment of complement-mediated diseases.
Regeneron is advancing a phase III study of cemdisiran and pozelimab combination for treating myasthenia gravis.
Alnylam records collaboration revenues from its collaboration with REGN.
Zacks Rank & Stocks to Consider
Alnylam currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimates have narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.